Rectal lymphogranuloma venereum (LGV) has reemerged as a sexually transmitted infection among men who have sex with men (MSM), particularly those who are HIV-positive. We undertook a systematic review and meta-analysis to determine the efficacy of doxycycline (100 mg 2×/d for 21 days) for rectal LGV in MSM. Nine studies were included: 4 prospective, 4 retrospective, and 1 combined retrospective and prospective. In total, 282 MSM with rectal LGV were included in the studies. All studies reported using nucleic acid amplification tests to assess microbial cure. Most patients (>80%) had symptomatic rectal infection. The fixed-effects pooled efficacy for doxycycline was 98.5% (95% CI 96.3%–100%, $I^2 = 0%$; $p = 0.993$). Doxycycline at 100 mg twice daily for 21 days demonstrated a high microbial cure rate. These data support doxycycline at this dosage and duration as first-line therapy for rectal LGV in MSM.

Lymphogranuloma venereum (LGV) has reemerged since the early 2000s as a cause of proctitis in men who have sex with men (MSM). Rectal LGV infections in MSM have been associated with high-risk sexual behaviors, increased rates of concurrent sexually transmitted infections (STIs), and hepatitis C, and the infections have been overrepresented among HIV-positive MSM (1). During 2003–2012, a total of 2,138 LGV cases were diagnosed in the United Kingdom: 98% were in MSM, of whom 80% were HIV-positive and 20% had hepatitis C infection (2). Surveys from Spain and Germany have shown that rectal LGV accounts for 8%–16% of rectal chlamydia infections in MSM (3,4).

LGV is caused by Chlamydia trachomatis serovars L1–L3 which, following mucosal inoculation, disseminate via underlying tissue to regional lymph nodes. This infection process contrasts with that of chlamydia infections caused by C. trachomatis serovars A–K, which are limited to the mucosa (5). Prior to the 21st century, LGV was endemic to Southeast Asia, the Caribbean, Latin America, and Africa, where infections mainly involved genital inoculation and ulceration with lymphatic spread, resulting in bubo formation (5,6). More recently, LGV infections among MSM have been largely attributable to the L2b variant of C. trachomatis and have predominantly presented as rectal infections following inoculation of the rectal mucosa (3). Compared with MSM who have rectal infections caused by chlamydia strains unrelated to LGV, MSM who have rectal LGV are more likely to have symptoms of proctitis and more likely to be HIV-positive (7). Symptomatic proctitis is a syndrome commonly seen among MSM attending STI clinics; cases caused by LGV and other sexually acquired pathogens are often clinically indistinguishable (8,9). Exudative proctitis has frequently been observed, by proctoscopy, in patients with rectal LGV (10,11). Asymptomatic rectal LGV also occurs and has accounted for different proportions of LGV cases in various studies (7,12,13).

A comparative study published in 1957 provided early evidence for the efficacy of tetracyclines for reducing bubo duration when used for 14 days (14). Several national and regional guidelines currently recommend doxycycline (100 mg 2×/d for 21 d) as first-line therapy for rectal LGV (5,6,15,16). The deep-seated nature of LGV infection is one rationale for this 3-week duration of treatment (12). In a prospective study using repeated testing to verify response to therapy, rectal chlamydia RNA was detectable for up to 16 days following commencement of doxycycline treatment, adding weight to the need for a longer course of doxycycline for LGV (17). However, several case reports
have described doxycycline failing to cure LGV in MSM despite 21 days of therapy, including cases of LGV buboes and rectal LGV (18–21). To provide an evidence base for the use of doxycycline as treatment for rectal LGV infections in MSM, we conducted a systematic review and meta-analysis of studies reporting microbial cure among MSM with rectal LGV treated with 100 mg doxycycline twice daily for 21 days.

Methods

Protocol and Registration
This systematic review and meta-analysis was conducted and reported according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Statement (http://prisma-statement.org/). The study protocol was registered with PROSPERO (International Prospective Register of Systematic Reviews, http://www.crd.york.ac.uk/PROSPERO/; registration no. CRD42016036038).

Search Strategy
Six electronic bibliographic databases (Medline, Embase, PubMed, ClinicalTrials.gov, Cochrane Central Register of Controlled Trials, and the Australian New Zealand Clinical Trials Registry) were searched for studies from 1940 to February 2016. In addition, we hand-searched conference abstracts that were available from the International Society for Sexually Transmitted Diseases Research for 2003–2013 and from the International Union against Sexually Transmitted Infections for 2009–2015; we also searched the reference lists of identified papers. Only abstracts published in English were included in the review. No attempt was made to identify unpublished studies.

We used the following search terms: “lymphogranuloma venereum” or “LGV” or “lymphogranuloma venereum” and “treatment” or “LGV and treatment.” Medical subject headings (MeSH) were used where possible. To capture all relevant articles, we did not restrict the search strategy specifically to doxycycline or rectal LGV.

Inclusion and Exclusion Criteria
We searched for any published studies providing data on microbial cure of rectal LGV in MSM. Patients were considered cured if a repeat anal swab sample was negative for C. trachomatis by nucleic acid amplification testing (NAAT) after treatment with 100 mg doxycycline twice daily for 21 days. So that study cure rates could be included in the meta-analysis, we required the following data for study inclusion: 1) the number of MSM with rectal LGV treated with 100 mg doxycycline twice daily for 21 days; 2) the number of these men who had repeat testing for rectal chlamydia infection following this treatment; and 3) the results of repeat testing for rectal chlamydia infection.

Studies with bisexual men were included as studies with MSM. For studies in which the 3 data above were not clear from the published papers or abstracts, we contacted authors to directly request the information. If the information was obtained, the studies and their data were included in the meta-analysis. Studies were excluded if 1) cure rates for rectal infection specifically, as distinct from inguinal buboes, could not be obtained; 2) the total sample size of the study was <10; 3) infections were in heterosexual men only; or 4) if different drugs or dosing regimens were used. Conference abstracts were also included if they fulfilled the inclusion criteria.

Data Extraction Process
We extracted the following data from each study: study design, treatment administered, sample size, proportion of rectal LGV infections that were symptomatic, the diagnostic method for assessing microbial cure, attrition rate of study subjects, and microbial cure after treatment. One author (C.L.) undertook selection of studies, and another (J.J.O.) checked the selection. Disagreements were resolved by discussion and consultation with a third author (M.C.) until a consensus was reached.

Outcome
Treatment efficacy for doxycycline, as determined by microbial cure, was calculated by using the number of treated men with a negative repeat test result by NAAT as the numerator and the number of treated men who underwent repeat testing as the denominator. A single C. trachomatis–negative anal swab sample after treatment was considered confirmation of microbial cure. Likewise, a repeat anal swab test positive for a chlamydia strain genotype not associated with LGV was also considered confirmation of cure but was associated with chlamydia reinfection.

Analysis
Meta-analysis was applied to calculate the pooled estimates of doxycycline efficacy. We used the $I^2$ test to estimate the approximate proportion of variability in point estimates attributed to heterogeneity other than that due to chance (22). Random-effects model results were shown if $I^2$ was >25%, and fixed-effects model results were shown if $I^2$ was ≤25%.

Assessment of Bias and Quality
Publication bias was not assessed using a funnel plot because <10 studies met the inclusion criteria (23). Two authors (C.L. and J.J.O.) independently assessed within-study bias using evaluation criteria reported elsewhere (24). Any discrepancies were resolved by recourse to a third author (M.C.). Meta-analysis was conducted using STATA version 13 (StataCorp LP, College Station, TX, USA).
Results

Study Selection and Characteristics
We reviewed 93 of 2,037 identified studies; 9 met our inclusion criteria (Figure 1; Table 1). Five studies were presented in published articles (3,17,25–27), and 4 were presented as conference abstracts (28–31). For 6 of these 9 studies, we obtained additional data on rectal microbial cure rates through personal communications so that the studies could be included in our analysis (Table 1) (3,26,28–31). In 1 study, 100 mg doxycycline twice daily for 21 days was used as the comparator group; we used the microbial cure in the doxycycline group in our meta-analysis (31).

Of the 9 studies, 4 were prospective (3,17,27,31), 4 were retrospective (26,28–30), and 1 was combined prospective and retrospective (25). All studies used NAAT for retesting after treatment. From these studies, data for a total of 282 MSM with rectal LGV who were retested after treatment with doxycycline were available and included in our meta-analysis. Eight studies reported that >80% of men had rectal symptoms when they sought medical care (3,25–31). All but 2 studies (3,25) reported the average time between treatment and repeat testing. A study by de Vries et al. (17) was the only study that undertook multiple repeat testing over time after doxycycline treatment; for the purposes of our analysis, we used the results from week 3 of the study because some men were given additional courses of doxycycline beyond 21 days. Five studies that reported attrition rates for repeat testing and the percentage of men who had repeat testing ranged from 0 to 65% (17,26,27,30,31).

Treatment Efficacy
The microbial cure rates for each of the 9 studies ranged from 95% (95% CI 76%–99%) (29) to 100% (95% CI 88%–100%) (31). Based on these 9 studies, the fixed-effects pooled efficacy was 98.5% (95% CI 96.3%–100%; \( I^2 = 0\% \); \( p = 0.993 \)) (Figure 2).

Study Bias
We assessed the risk of biases within each of the 9 included studies (Table 2; online Technical Appendix Table, http://wwwnc.cdc.gov/EID/article/22/10/16-0986-Techapp1.pdf). Of the 9 studies, 7 recruited patients from STI clinics (3,25–29,31); 8 recruited MSM regardless of whether they had rectal symptoms (3,17,25–28,30,31); and 1 recruited only patients with symptomatic proctitis (29). All studies described in-house methods for LGV identification: 2 used a real-time PCR targeting the polymorphic membrane protein H gene (17,26); 1 used nested PCR and restriction fragment length polymorphism (RFLP) analysis targeting the major outer membrane protein gene (25); 1 used real-time multiplex PCR including LGV (31); 1 used...
Doxycycline for Rectal Lymphogranuloma Venereum

Table 1. Studies from 2006 to 2015 reporting the efficacy of 100 mg doxycycline twice daily for 21 days for the treatment of rectal LGV in men who have sex with men*

<table>
<thead>
<tr>
<th>Ref.</th>
<th>Study type</th>
<th>Serovar</th>
<th>No. men tested positive and treated for LGV/no. retested after treatment</th>
<th>No. symptomatic/no. total (%)</th>
<th>No. HIV-positive/no. total (%)</th>
<th>Method for retesting</th>
<th>Time from treatment to retesting</th>
<th>No. negative repeat tests results/no. repeat tests (%) negative; repeat tests (%)</th>
<th>Study type</th>
<th>Serovar</th>
<th>No. men tested positive and treated for LGV/no. retested after treatment</th>
<th>No. symptomatic/no. total (%)</th>
<th>No. HIV-positive/no. total (%)</th>
<th>Method for retesting</th>
<th>Time from treatment to retesting</th>
<th>No. negative repeat tests results/no. repeat tests (%) negative; repeat tests (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>(25)</td>
<td>RS/PS</td>
<td>L2</td>
<td>21/21</td>
<td>5/21 (24%)</td>
<td>13/21 (62%)</td>
<td>Cobas Amplicor Analyzer†</td>
<td>NS</td>
<td>21/21 (100; 85–100)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(17)</td>
<td>PS</td>
<td>L</td>
<td>20/17</td>
<td>NS</td>
<td>NS</td>
<td>Cobas Amplicor Analyzer†</td>
<td>3 wk</td>
<td>17/17 (100; 82–100)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(26)</td>
<td>RS</td>
<td>L</td>
<td>55/19</td>
<td>59/63 (94)</td>
<td>52/63 (82)</td>
<td>BD ProbeTec ET System‡</td>
<td>3 mo</td>
<td>19/19 (100; 83–100)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(28)</td>
<td>RS</td>
<td>L</td>
<td>70/70</td>
<td>80/99 (81)</td>
<td>78/99 (79)</td>
<td>BD ProbeTec ET System‡</td>
<td>≤6 mo</td>
<td>68/69 (99; 92–100)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(29)</td>
<td>RS</td>
<td>L2b</td>
<td>20/20</td>
<td>20/20 (100)</td>
<td>18/25 (72)</td>
<td>BD ProbeTec ET System‡</td>
<td>3 mo</td>
<td>19/20 (95; 76–99)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(30)</td>
<td>RS</td>
<td>L</td>
<td>80/43</td>
<td>71/83 (85)</td>
<td>69/83 (83)</td>
<td>APTIMA Combo 2 assay**</td>
<td>6 wk</td>
<td>42/43 (97; 88–100)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(27)</td>
<td>PS</td>
<td>L2</td>
<td>13/13</td>
<td>13/13 (100)</td>
<td>9/13 (69)</td>
<td>Versant CT/GC DNA 1.0 assay††</td>
<td>3 mo</td>
<td>13/13 (100; 77–100)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(3)</td>
<td>PS</td>
<td>L2, L2b</td>
<td>53/53</td>
<td>73/82 (89)</td>
<td>66/82 (80)</td>
<td>Abbott RealTime CT/NG assay¶¶, BD ProbeTec ET System‡</td>
<td>NS</td>
<td>51/53 (96; 87–99)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(31)</td>
<td>PS</td>
<td>L</td>
<td>28/27</td>
<td>28/28 (100)</td>
<td>27/28 (96)</td>
<td>Real-time multiplex PCR</td>
<td>3 wk</td>
<td>27/27 (100; 88–100)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*LGV, lymphogranuloma venereum; NS, not specified; PS, prospective; ref., reference; RS, retrospective; RS/PS, retrospective and prospective.
†Roche, Basel, Switzerland.
‡Becton Dickinson Microbiology Systems, Sparks, MD, USA.
¶Seven men treated for rectal LGV underwent repeat testing; 1 had an equivocal result and was excluded from further analyses (S. Pallawela, Royal Berkshire Hospital, Reading, UK, pers. comm., 2016 Apr 28).
§§J.C. Galan, Hospital Ramon y Cajal, Madrid, Spain, pers. comm., 2016 May 16.
‡‡Siemens Healthcare Diagnostics, Tarrytown, NY, USA.
¶¶Abbott Laboratories, Des Plaines, IL, USA.
###J.L. Blanco, University of Barcelona, Barcelona, Spain, pers. comm., 2016 May 10.

PCR amplification of the outer membrane protein 1 (omp1) gene followed by RFLP analysis (27); 1 used omp1 gene sequencing (29); 1 used real-time polymorphic membrane protein H gene PCR and omp1 gene sequencing (3); 1 used LGV-specific molecular serovar typing (28); and 1 used an in-house assay (30).

Studies differed in the manner in which they dealt with the possibility of LGV reinfection or non-LGV chlamydia as a cause of a positive test result after treatment. Three studies with participants whose repeat test results were positive reported that reinfection could have contributed to these results (28–30). Six of the studies conducted genotyping of positive repeat chlamydia specimens (17,26,27,29–31). Two of these studies reported genotyping results: Foschi et al. (27) reported that 1 patient had a non-LGV serovar on repeat testing, indicating chlamydia reinfection, and Bisessor et al. (29) demonstrated an LGV-associated serovar in a sample from a man who had unprotected sexual intercourse after treatment, making it impossible to determine whether the infection was due to treatment failure or reinfection. None of the studies reported the application of stringent criteria or algorithms, such as an algorithm based on a combination of sexual reexposure and chlamydia genotyping (32), to distinguish treatment failure from reinfection. All but 1 study used microbial cure on a single repeat test.

None of the studies discussed compliance with the full course of doxycycline or the concurrent use of other antimicrobial drugs, both of which could influence treatment outcomes. Three studies reported the authors’ conflicts of interest and funding sources (3,17,27). Through the review process, no randomized controlled trials comparing doxycycline with other treatments were identified.

**Discussion**

Our meta-analysis found a pooled treatment efficacy of 98.5% (96.3%–100%; I² = 0%) for 100 mg doxycycline twice daily for 21 days for the treatment of rectal LGV infections in MSM. This result supports the recommendation that doxycycline be used at this dosage and duration for the treatment of rectal LGV in MSM, including MSM who are HIV-positive. Several guidelines, including those from Europe, the United Kingdom, and the United States, recommend doxycycline at this dosage and duration as...
rectal chlamydia are needed. In a prospective study of rectal LGV treatment, 100 mg doxycycline twice daily for 7 days achieved a negative repeat chlamydia test result for only 15 (88%) of 17 MSM (17). Persistent rectal LGV infection despite 10 days of doxycycline treatment has also been reported (18). These reports underscore the value of genotyping positive rectal chlamydia specimens from MSM because the identification of LGV-associated variants will indicate the need for a longer course of doxycycline to ensure cure.

Although our meta-analysis showed that most rectal LGV infections were cured with a 21-day course of doxycycline, clinical failures have been reported with this regimen. In a case from France, an HIV-negative man with LGV proctitis and inguinal lymphadenopathy from the L2 serovar experienced clinical antimicrobial drug treatment failure even though doxycycline treatment was extended beyond 3 weeks. He subsequently achieved clinical resolution with moxifloxacin (18). In a report from Portugal, 2 HIV-positive MSM with rectal LGV from the L2b variant (1 with inguinal lymphadenopathy and the other with fever) did not clinically respond after 3 weeks’ treatment with doxycycline (19). In a case from Spain, a man with L2 serovar–associated LGV proctitis and inguinal lymphadenopathy received 200 mg doxycycline daily for 21 days, resulting in improved rectal symptoms, but progression of the lymphadenopathy required azithromycin followed by moxifloxacin to achieve clinical cure (20). There have also been reports of LGV buboes in MSM that have not resolved clinically after treatment with doxycycline for 21 days. In some cases, abscess formation and rupture with sinus formation have occurred despite this course of treatment (21,34). These reports suggest that in some cases of more clinically severe or extensive rectal LGV infection, 3 weeks’ treatment with doxycycline may not be sufficient for clinical and microbial cure. When abscesses are present, treatment failure might reflect poor penetration of antimicrobial drugs. Several national guidelines recommend that LGV infections be clinically observed until completely resolved and that routine test of cure is not necessary if a

---

**Table 2.** Summary of risk of bias in studies from 2006 to 2015 included in a systematic review and meta-analysis of the efficacy of doxycycline for rectal lymphogranuloma venereum in men who have sex with men

<table>
<thead>
<tr>
<th>Ref.</th>
<th>Method for selection of participants</th>
<th>Methods for measuring exposure and outcome variables</th>
<th>Design-specific sources of bias, excluding confounding</th>
<th>Method to control confounding</th>
<th>Statistical methods</th>
<th>Conflict of interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>(25)</td>
<td>+</td>
<td>+</td>
<td>NR</td>
<td>NR</td>
<td>+</td>
<td>NR</td>
</tr>
<tr>
<td>(17)</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>NR</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>(26)</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>NR</td>
<td>+</td>
<td>NR</td>
</tr>
<tr>
<td>(28)</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>NR</td>
<td>+</td>
<td>NR</td>
</tr>
<tr>
<td>(29)</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>NR</td>
<td>+</td>
<td>NR</td>
</tr>
<tr>
<td>(30)</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>NR</td>
<td>+</td>
<td>NR</td>
</tr>
<tr>
<td>(27)</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>NR</td>
<td>+</td>
<td>NR</td>
</tr>
<tr>
<td>(3)</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>NR</td>
<td>+</td>
<td>NR</td>
</tr>
<tr>
<td>(31)</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>NR</td>
<td>+</td>
<td>NR</td>
</tr>
</tbody>
</table>

*NR, not reported; ref., reference; +, low risk of bias; ++, moderate risk of bias; ++++, high risk of bias.
21-day course of doxycycline has been completed (5,6,15). Our study findings support these recommendations.

Cases of rectal LGV among MSM have mainly been attributable to *C. trachomatis* serovars L2b and L2. Co-circulation of these 2 serovars among MSM in Spain has been shown with distinct clinical manifestations: LGV cases with rectal bleeding and pain have been associated with serovar L2b more than with L2 (3). Previous studies have, however, reported failure of doxycycline treatment in patients infected with the L2 serovar (18,20). Recently, a new LGV strain, L2c, a recombination of L2 and D strains, has been identified and may be associated with more severe infection (35). However, *C. trachomatis* serovar L, compared with serovars D–K, has no additional genes that determine disease outcome (36,37). Further research is required to define the determinants of LGV invasiveness and pathogenesis (37).

Several points should be considered when interpreting the results of our study. We identified only 9 studies that specifically reported microbial cure rates for MSM with rectal LGV, 4 of which were conference abstracts rather than published papers. The overall pooled efficacy of doxycycline was based on results for a total of 282 men. Although this combined number of cases is limited, the pooling together of otherwise small, individual studies provides a more precise estimate of doxycycline efficacy with tighter CIs than was previously available for each of the separate component studies (Table 1). Only 4 studies were prospective, and several were retrospective studies. We did not identify any randomized controlled trials. We identified considerable limitations in the quality of studies. The studies showed considerable variation in the timing of repeat testing after doxycycline, and only 1 study undertook repeat testing on more than 1 occasion (17). A single negative repeat test could, in theory, miss ongoing infection if organism shedding is intermittent and thus could lead to an overestimation of treatment efficacy (38). Conversely, a positive repeat test could indicate reinfection with LGV or another chlamydia strain rather than treatment failure, leading to an underestimation of treatment efficacy. None of the studies reported criteria or algorithms, as described previously (32), to distinguish treatment failure from reinfection based on sexual reexposure and chlamydia genotyping. Future randomized trials aimed at determining the efficacy of alternative antimicrobial drugs for the treatment of LGV are warranted and should include carefully considered algorithms that distinguish treatment failure from reinfection.

Despite these caveats, our study demonstrated a high microbial cure rate for 100 mg doxycycline twice daily for 21 days for the treatment of rectal LGV in MSM. The data support doxycycline at this dosage and duration as first-line therapy for rectal LGV.

Acknowledgments
We thank Stephen P. Higgins, Anna Garner Louise, Juan-Carlos Galán, Sanjeeva Pallawela, Samantha Hill, and José Luis Blanco Arévalo for additional data.

E.P.F.C. and J.J.O. are supported by the Early Career Fellowship from the Australian National Health and Medical Research Council (nos. 1091226 and 1104781, respectively).

Dr. Leeaphan, an instructor in the Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, in Bangkok, Thailand, undertook research for this study during her position as Research Fellow at the Melbourne Sexual Health Centre, Alfred Health, in Melbourne, Australia. Her primary research interests are the epidemiology and dermatologic manifestations of sexually transmissible infections.

References

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 22, No. 10, October 2016


Address for correspondence: Marcus Chen, Central Clinical School Monash University, Melbourne Sexual Health Centre, 580 Swanston St, Carlton, VIC 3053, Australia; email: mchen@mshec.org.au
Systematic Review and Meta-Analysis of Doxycycline Efficacy for Rectal Lymphogranuloma Venereum in Men Who Have Sex with Men

Technical Appendix

Technical Appendix Table. Risk bias assessment for included studies.

<table>
<thead>
<tr>
<th>Study, bias</th>
<th>Judgment</th>
<th>Support for judgment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods for selection of participants</td>
<td>Low risk</td>
<td>Setting where patients were recruited: Reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>– Quote: “The study was conducted at the STI clinic of the Department of Dermatology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>and Venerology, Erasmus MC Rotterdam, Netherlands”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Selection of MSM with rectal LGV infection: Reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>– Quote. “All patients attended the STI clinic on their own initiative because of</td>
</tr>
<tr>
<td></td>
<td></td>
<td>symptoms related to STI or sexual risk behavior.”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>– Quote. “Rectal tests for gonococcal and chlamydial infection were performed as a</td>
</tr>
<tr>
<td></td>
<td></td>
<td>routine in all MSM.”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Genotyping was done prospectively in all rectal chlamydial infections ……February</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2003. 33 (15.1%) rectal Chlamydia trachomatis infections from the years 2001 and 2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>were genotyped retrospectively.”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Method for LGV identification: Reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>– Quote. “Genotyping of the gene encoding the major outer membrane protein (MOMP) was</td>
</tr>
<tr>
<td></td>
<td></td>
<td>performed by nested PCR and restriction fragment length polymorphism (RFLP) analysis”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Methods for measuring exposure and outcome variables</td>
</tr>
<tr>
<td></td>
<td>Low risk</td>
<td>Doxycycline 100 mg twice daily for 21 d was used as treatment: Reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>– Quote. “….and (suspected) LGV infections with doxycycline 100 mg orally twice daily</td>
</tr>
<tr>
<td></td>
<td></td>
<td>for 3 weeks”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Method used for repeat test after treatment: Reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>– Quote. “….the automated C. trachomatis Cobas Amplicor PCR system was used throughout</td>
</tr>
<tr>
<td></td>
<td></td>
<td>the study…”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Timing of the test of cure: Not reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>– Quote. “Post-treatment swabs were only taken in those with LGV. All infections with</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LGV cleared after treatment with doxycycline.”</td>
</tr>
<tr>
<td>Design-specific sources of bias (excluding</td>
<td>Not reported</td>
<td>Drug compliance: Not reported</td>
</tr>
<tr>
<td>confounding)</td>
<td></td>
<td>Sexual re-exposure as potential cause of repeat positivity: Not reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Genotype of positive repeat specimen for discrimination between reinfection and</td>
</tr>
<tr>
<td></td>
<td></td>
<td>treatment failure: Not reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Antibiotic use shortly before doxycycline or before repeat testing: Not reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>– Not reported</td>
</tr>
<tr>
<td>Methods to control confounding Statistical</td>
<td>Not reported</td>
<td>Low risk</td>
</tr>
<tr>
<td>methods</td>
<td></td>
<td>– Descriptive analysis used. No sample size calculation.</td>
</tr>
<tr>
<td>Study, bias</td>
<td>Judgment</td>
<td>Support for judgment</td>
</tr>
<tr>
<td>-------------</td>
<td>----------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Conflict of interest</td>
<td>Not reported</td>
<td>Not reported</td>
</tr>
</tbody>
</table>

### De Vries HJ, 2009

#### Methods for selection of participants
- **Low risk**
  - Setting where patients were recruited: Not reported
  - Selection of MSM with rectal LGV infection: Reported
    - Quote. “…all men reporting receptive anal sex in the previous 6 months were routinely checked for chlamydia proctitis by collection of mucosal swab specimens during anoscopy”
    - Quote. “Patients with chlamydia proctitis were asked at random for written consent to participate,… For all patients, biovar-L analysis of chlamydia-positive anal swab specimens was performed.”
    - Participants who missed >1 visit were excluded. Quote. “Thirty-one male patients with LGV proctitis and 31 with non-LGV chlamydia proctitis were included in the study. Eleven patients with LGV proctitis and 5 with non-LGV chlamydia proctitis missed >1 study visit and were excluded.”
    - Quote. “…biovar-L analysis of chlamydia-positive anal swab specimens was performed, as described elsewhere [10, 11].”

#### Methods for measuring exposure and outcome variables
- **Low risk**
  - Doxycycline 100 mg twice daily for 21 d was used as treatment: Reported
    - Quote. “If LGV proctitis was diagnosed (by biovar-L analysis) the doxycycline course was prolonged for 21 days.”
  - Method used for repeat test after treatment: Reported
    - Quote. “…chlamydia DNA was detected by Cobas Amplicor (Roche, Basel, Switzerland)…”
  - Timing of the test of cure: Reported.
    - Quote. “Anal swab specimens were collected at subsequent visits during weeks 1, 2, 3, and 6 ...... after the commencement of doxycycline treatment).”

#### Design-specific sources of bias (excluding confounding)
- **Low risk**
  - Repeated testing overtime after treatment conducted at week 1, 2, 3 and 6.
    - Quote. “Anal swab specimens were collected at subsequent visits during weeks 1, 2, 3, and 6 ...... after the commencement of doxycycline treatment).”
  - Drug compliance: Not reported
  - Sexual re-exposure as potential cause of repeat positivity: Reported
    - Quote. “During this follow-up period, patients were asked to refrain from sexual contact.”
  - Genotype of positive repeat specimen for discrimination between reinfection and treatment failure: Reported
    - Quote. “During this follow-up period….For chlamydia DNA–positive samples, biovar-L determination was performed”
  - Antibiotic use shortly before doxycycline or before repeat testing: Reported
    - There were additional treatments in 5 patients prior test of cure at 6 week.
    - Quote. “At the end of therapy (week 3 visit), LGV proctitis persistent mucous membrane abnormalities were observed in 6 of 16 patients during anoscopy examination. For this reason, doxycycline treatment was prolonged for an additional 21 days for 5 of these 6 patients…all patients with LGV who had mucosal abnormalities after therapy completion showed microbial cure within the first week.”

#### Methods to control confounding
- **Not reported**

#### Statistical methods
- **Low risk**
  - Not reported
  - Descriptive analysis used. No sample size calculation.
  - Quote. “Financial support. Research and Development Fund of the Health Service Amsterdam. Potential conflicts of interest. All authors: no conflicts”

### Hill S, 2010

#### Methods for selection of participants
- **Low risk**
  - Setting where patients were recruited: Reported
    - Quote. “The aim of this study was to audit the management of LGV within a large sexual health clinic in London, UK”
  - Selection of MSM with rectal LGV infection: Reported
<table>
<thead>
<tr>
<th>Study, bias</th>
<th>Judgment</th>
<th>Support for judgment</th>
</tr>
</thead>
</table>
| Methods for measuring exposure and outcome variables                      | Low risk          | - Retrospective study that reviewed all episodes of LGV. No criteria reported for patient selection for rectal chlamydia testing and genotyping.  
  - Quote. "We performed a retrospective case-note review of all patients with confirmed LGV between June 2005 and May 2009."  
  - Quote. "Sixty-three episodes of LGV were diagnosed in 60 MSM...Three patients had two episodes of LGV during the audit period."  
  - Method for LGV identification: Reported  
  - Quote. "...real time PCR for the detection of LGV-specific DNA was performed..."  
  - Doxycycline 100 mg twice daily for 21 d was used as treatment: Reported  
  - Quote. "Fifty-five patients were treated with doxycycline in accordance with BASHH guidelines."  
  - Method used for repeat test after treatment: Reported  
  - Quote. "Specimens were tested for CT using the BD ProbeTecTM ET System (Becton Dickinson Microbiology Systems, Sparks, MD, USA)."  
  - Timing of the test of cure: Reported  
  - Quote. "...19 underwent TOC within three months of completing treatment."  
| Design-specific sources of bias (excluding confounding)                   | Moderate risk     | - Drug compliance: Not reported  
  - Sexual re-exposure as potential cause of repeat positivity: Not reported  
  - Genotype of positive repeat specimen for discrimination between reinfection and treatment failure: Reported  
  - Genotyping was undertaken in patients with positive rectal cases. Absence of LGV detection on repeat testing was classified as microbial cure in this study.  
  - Quote. "Twenty-one (87%) patients tested negative, and three (13%) tested positive for rectal CT – all with non-LGV strains"  
| Methods to control confounding                                           | Not reported      | - Antibiotic use shortly before doxycycline or before repeat testing: Not reported  
| Statistical methods                                                      | Low risk          | - Descriptive analysis used. No sample size calculation.  
| Conflict of interest                                                    | Not reported      | - Not reported  

| Pallawela S, 2010                                                        | Low risk          | - Setting where patients were recruited: Reported  
  - Quote. "A retrospective case note review was conducted in 6 GUM/HIV clinics in London."  
| Methods for selection of participants                                    |                   | - Selection of MSM with rectal LGV infection: Reported  
  - Retrospective study reviewing all LGV cases with test of cure. Quote. "We identified 226 LGV MSM, of these 99 (44%) had a TOC within 6 months.  
  - From personal communication "There were 99 MSM with rectal LGV who underwent a repeat test included in this study."  
| Methods for measuring exposure and outcome variables                    | Low risk          | - Method for LGV identification: Reported  
  - Quote. "...LGV-specific molecular serovar typing"  
  - Doxycycline 100 mg twice daily for 21 d was used as treatment: Reported  
  - Quote. "The vast majority (94%) were treated with the recommended regimen of doxycycline"  
  - From personal communication "Of 99 MSM with rectal LGV, 70 patients received doxycycline 100 mg twice daily for 21 days."  
| Methods for measuring exposure and outcome variables                    |                   | - Method used for repeat test after treatment: Reported  
  - Quote. "The standard test used for detecting Chlamydia trachomatis was the Becton Dickinson ProbeTecTM ET assay"  
| Methods for measuring exposure and outcome variables                    |                   | - Timing of the test of cure: Reported  
  - Quote. "...these 99 (44%) had a test of cure within 6 months..... The median time post treatment to test of cure was 68 days (range 17-185)."
Study, bias | Judgment | Support for judgment
---|---|---
Design-specific sources of bias (excluding confounding) | Moderate risk | – Drug compliance: Not reported
 – Sexual re-exposure as potential cause of repeat positivity: Reported
   – Quote. “One patient had an indeterminate test and one an equivocal result with high suspicion of re-infection: both tests were done before the recommended time.”
 – Genotype of positive repeat specimen for discrimination between reinfection and treatment failure: Not reported
 – Antibiotic use shortly before doxycycline or before repeat testing: Not reported
Methods to control confounding | Not reported | – Not reported
Statistical methods | Low risk | – Descriptive analysis used. No sample size calculation.
Conflict of interest | Not reported | – Not reported

**Bissessor M, 2011**

Methods for selection of participants | Low risk | – Setting where patients were recruited: Reported
   – Quote. “We reviewed all cases of LGV seen at the Melbourne Sexual Health Centre between 2005 and 2010”
 – Selection of MSM with rectal LGV infection: Reported
 – Method for LGV identification: Reported.
   – Quote. “During this period MSM who were diagnosed with rectal chlamydia using strand displacement assay were routinely questioned about symptoms of proctitis using a symptom check list. Those with symptoms of proctitis had specimens forwarded for Chlamydia trachomatis omp1 genotyping.”
 – Doxycycline 100 mg twice daily for 21 d was used as treatment: Reported
   – Quote. “All but one of the LGV infected men received at least a 3-week course of doxycycline 100 mg twice daily.” Personal communication “There were 20 men with rectal LGV who received doxycycline and had a repeat test.”
 – Method used for repeat test after treatment: Reported
   – Quote. “…..diagnosed with rectal chlamydia using strand displacement assay”
 – Timing of the test of cure: Reported for only cases with a positive repeat test.
   – Quote. “Both these patients were noted to have had unprotected sex following initial treatment, hence, it is unclear whether this was due to treatment failure or reinfection.”
 – Drug compliance: Not reported
 – Sexual re-exposure as potential cause of repeat positivity: Reported
   – Quote. “Both these patients were noted to have had unprotected sex following initial treatment, hence, it is unclear whether this was due to treatment failure or reinfection.”
 – Genotype of positive repeat specimen for discrimination between reinfection and treatment failure: Reported
   – Quote. “Two men with ano-rectal LGV remained LGV positive on follow-up when tested 3 months later.”
 – Antibiotic use shortly before doxycycline or before repeat testing: Not reported

Methods for measuring exposure and outcome variables | Low risk | – Not reported

**Vas A, 2013**

Methods for selection of participants | Low risk | – Setting where patients were recruited: Reported
   – Quote. “A three-centre retrospective cases note analysis” These three centers were Manchester Royal Infirmary; North Manchester General Hospital and Withington Community Hospital, Manchester, UK.
 – Selection of MSM with rectal LGV infection: Reported
   – Quote. “…83 patients diagnosed with LGV in Greater Manchester was performed. All patients were men and men who have sex with men (MSM)…” Personal communication “There were 43 men with rectal LGV who received doxycycline and had a repeat test in their clinic.”
 – Method for LGV identification: Not reported
<table>
<thead>
<tr>
<th>Study, bias</th>
<th>Judgment</th>
<th>Methods for measuring exposure and outcome variables</th>
</tr>
</thead>
</table>
|            | Low risk | - Doxycycline 100 mg twice daily for 21 d was used as treatment: Reported  
|            |          |   - Quote. “All patients received first line treatment with a three-week course of doxycycline 100 mg twice daily orally.”  
|            |          |   - Method used for repeat test after treatment: Reported  
|            |          |   - Personal communication “An in house assay was used for chlamydia and LGV detections.”  
|            |          |   - Timing of the test of cure: Reported  
|            |          |   - Quote. “Test of cure at six weeks was documented in 52/83 cases and performed in 46 cases.” |
|            | Moderate risk | Design-specific sources of bias (excluding confounding) |
|            |                | - Drug compliance: Not reported  
|            |                | - Sexual re-exposure as potential cause of repeat positivity: Not reported  
|            |                |   - Quote. “…one tested positive which was likely secondary to re-infection.”  
|            |                | - Genotype of positive repeat specimen for discrimination between reinfection and treatment failure: Reported  
|            |                |   - Personal communication “For test of cure, if chlamydia was positive, it was sent for LGV serovar testing.” |
|            | Not reported | Methods to control confounding |
|            | Low risk | - Descriptive analysis used. No sample size calculation. |
|            | Not reported | Statistical methods |
| Conflict of interest | Not reported | - Descriptive analysis used. No sample size calculation. |

<table>
<thead>
<tr>
<th>Foschi C, 2014</th>
<th>Methods for selection of participants</th>
<th>Low risk</th>
</tr>
</thead>
</table>
| - Setting where patients were recruited: Reported  
| - Quote. “…patients attending the STI Outpatients Clinic of St. Orsola University Hospital of Bologna…”  
| - Selection of MSM with rectal LGV infection: Reported  
| - Quote. “From January 2012 to April 2013, all the patients attending…and reporting unsafe anal sexual intercourse, have been asked to carry out a clinical examination. An anorectal swab, a pharyngeal swab (if reporting oral sex intercourse) and an urine sample were collected from each patient for DNA detection of CT and Neisseria gonorrhoeae.”  
| - Quote. “In case of a CT positive result, molecular genotyping, based on omp1 gene semi-nested PCR, followed by RFLP analysis” |
| Methods for measuring exposure and outcome variables | Low risk | - Doxycycline 100 mg twice daily for 21 d was used as treatment: Reported  
| - Quote. “LGV positive patients were treated with doxycycline 100 mg twice a day for 3 weeks”  
| - Method used for repeat test after treatment: Reported  
| - Quote. “…anorectal and pharyngeal swabs were processed by Versant CT/GC DNA 1.0 Assay (Siemens Healthcare Diagnostics, Tarrytown, NY, USA), a Real-Time PCR test simultaneously detecting the presence of CT and/or GC DNA”  
| - Timing of the test of cure: Reported  
| - Quote. “Three months after treatment, rectal swabs and urine samples were negative both for CT and GC nucleic acids in all patients but one.” |
| Design-specific sources of bias (excluding confounding) | Moderate risk | - Drug compliance: Not reported  
| - Sexual re-exposure as potential cause of repeat positivity: Not reported  
| - Genotype of positive repeat specimen for discrimination between reinfection and treatment failure: Reported  
| - Quote. “This patient had a positive result for GC and a non-LGV serovar CT in his rectal swab, with recurrence of mild anal symptoms.” |
| Methods to control confounding | Not reported | - Antibiotic use shortly before doxycycline or before repeat testing: Not reported |
| Statistical methods | Low risk | - Descriptive analysis used. No sample size calculation. |
| Conflict of interest | Reported conflict of | - "The authors declare that they have no competing interests.” |
### Study, bias

<table>
<thead>
<tr>
<th>Study, bias</th>
<th>Judgment</th>
<th>Support for judgment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rodriguez-Domínguez M, 2013</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methods for selection of participants</td>
<td>Low risk</td>
<td>Setting where patients were recruited: Reported&lt;br&gt;Quote. “Two STI Units in Madrid, Spain, were involved in the present study. From March 2009 to November 2011 a total of 13,585 samples were collected from 8407 attendees, who came voluntarily for suspected STI as a consequence of sexual risk behavior.”&lt;br&gt;Selection of MSM with rectal LGV infection: Reported&lt;br&gt;Quote. “There were 81 MSM with rectal LGV infection enrolled in this study. They were more often detected in MSM (87/94, 92.5%), but in 2011, seven cases were diagnosed in the heterosexual population (four men and three women). The text and Table 1 reported 81 rectal LGV cases were from MSM and one case was from a woman.”&lt;br&gt;Method for LGV identification: Reported.&lt;br&gt;Quote. “The study was based on screening of <em>C. trachomatis</em> using commercial kits, followed by real-time pmpH-PCR discriminating LGV strains, and finally <em>ompA</em> gene was sequenced for phylogenetic reconstruction.”</td>
</tr>
<tr>
<td>Methods for measuring exposure and outcome variables</td>
<td>Low risk</td>
<td>Doxycycline 100 mg twice daily for 21 d was used as treatment: Reported&lt;br&gt;Quote. “doxycycline (100 mg/12 h for 3 weeks) was prescribed in 75 patients (80%).”&lt;br&gt;Method used for repeat test after treatment: Reported&lt;br&gt;Quote. “Screening of <em>C. trachomatis</em> was based on two molecular commercial tests: Abbott Real Time CT/NG (Abbott Laboratories, Des Plaines, IL, USA) was performed in one STI Unit, and BD-ProbeTec TM ET CT/GC (Becton Dickinson Diagnostic Systems, Sparks, MD, USA) in the second STI Unit…”&lt;br&gt;Timing of the test of cure: Not reported&lt;br&gt;Quote. “At the end of the treatment protocol 57/91 (63%) treated patients had their disease controlled.”&lt;br&gt;Drug compliance: Not reported&lt;br&gt;Sexual re-exposure as potential cause of repeat positivity: Not reported&lt;br&gt;Genotype of positive repeat specimen for discrimination between reinfection and treatment failure: Not reported&lt;br&gt;Antibiotic use shortly before doxycycline or before repeat testing: Not reported&lt;br&gt;There were 16 cases that were initially treated with a single dose of azithromycin 1 g but our study did not included these patients in our analysis. From personal communication “there were 54 MSM who received doxycycline alone and underwent a repeat test.”</td>
</tr>
<tr>
<td>Design-specific sources of bias (excluding confounding)</td>
<td>Not reported</td>
<td></td>
</tr>
<tr>
<td>Methods to control confounding</td>
<td>Not reported</td>
<td></td>
</tr>
<tr>
<td>Statistical methods</td>
<td>Low risk</td>
<td></td>
</tr>
<tr>
<td>Conflict of interest</td>
<td>Reported conflict of interest</td>
<td></td>
</tr>
<tr>
<td><strong>Blanco JL, 2015</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methods for selection of participants</td>
<td>Low risk</td>
<td>Setting where patients were recruited: Reported&lt;br&gt;Quote. “A longitudinal prospective study at the STD Unit in the Hospital Clinic was conducted in Barcelona between 6/2010 and 4/2014.”&lt;br&gt;Selection of MSM with rectal LGV infection: Reported&lt;br&gt;Quote. “Adult patients were eligible for inclusion if they presented with clinical manifestation of anorectal syndrome or any clinical suspicion of LGV infection after recent history of unsafe sex…. all MSM…”&lt;br&gt;Method for LGV identification: Reported.&lt;br&gt;Quote. “…assessed weekly by real-time multiplex polymerase chain reaction (M-PCR) that includes LGV”&lt;br&gt;Doxycycline 100 mg twice daily for 21 d was used as treatment: Reported&lt;br&gt;Quote. “If LGV was detected, at visit 1 (day +7) oral doxycycline 100 mg twice a day for 3 weeks”&lt;br&gt;Method used for repeat test after treatment: Reported</td>
</tr>
<tr>
<td>Study, bias</td>
<td>Judgment</td>
<td>Support for judgment</td>
</tr>
<tr>
<td>------------------------------------------------------</td>
<td>----------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| Design-specific sources of bias (excluding confounding) | Moderate risk | - Quote. “...real-time multiplex polymerase chain reaction (M-PCR) that includes LGV”  
- **Timing of the test of cure**: Reported.  
- Real time multiplex PCR was assessed in patients with doxycycline treatment at the end of treatment (day 21).  
- **Drug compliance**: Not reported  
- **Sexual re-exposure as potential cause of repeat positivity**: Not reported  
- **Genotype of positive repeat specimen for discrimination between reinfection and treatment failure**: Reported  
  - Quote. “...real-time multiplex polymerase chain reaction (M-PCR) that includes LGV”  
- **Antibiotics use shortly before doxycycline or before repeat testing**: Reported  
  - Quote. “All patients received a single dose of 1 g intramuscular ceftriaxone but were aleatorily assigned to receive, if LGV was detected, at visit 1 (day +7): (i) oral doxycycline 100 mg twice a day for 3 weeks; or (ii) azithromycin 1 g orally once weekly for 3 weeks.” |
| Methods to control confounding                        | Not reported | - Not reported                                                                                                                                 |
| Statistical methods                                   | Low risk  | - Descriptive analysis used. No sample size calculation.                                                                                                                                 |
| Conflict of interest                                  | Not reported | - Not reported                                                                                                                                 |